Brooklyn ImmunoTherapeutics, Inc.
(NYSE Amex Equities : BTX)

( )
BTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
MRKMerck & Co., Inc. -1.51%77.150.7%$1616.12m
JNJJohnson & Johnson -0.78%160.040.7%$1019.32m
PFEPfizer Inc. -0.48%41.290.9%$979.71m
ABBVAbbVie, Inc. -1.77%107.401.9%$706.34m
BMYBristol-Myers Squibb Co. -2.47%56.921.0%$674.83m
LLYEli Lilly & Co. 0.41%238.861.1%$632.00m
AZNAstraZeneca Plc -1.54%59.291.0%$371.26m
NVSNovartis AG -1.18%82.350.2%$175.26m
GSKGlaxoSmithKline Plc -0.90%38.660.2%$157.32m
RGENRepligen Corp. -1.18%263.786.8%$127.95m
AVIRAtea Pharmaceuticals, Inc. 3.36%40.600.3%$125.49m
CRVSCorvus Pharmaceuticals, Inc. -6.67%4.620.7%$102.55m
VTRSViatris, Inc. 0.22%13.490.0%$98.40m
NVONovo Nordisk A/S 1.10%103.470.1%$91.55m
RPRXRoyalty Pharma Plc -3.57%37.020.1%$83.95m

Company Profile

Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.